Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | Kidney cancer: post-surgery sorafenib

Tim Eisen, MBBChir, PhD, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK, describes the rationale and methodology behind the SORCE trial (NCT00492258) and what have we learned at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.